- Home
- AKRO vs HSAI Comparison
AKRO vs HSAI Comparison
Compare AKRO & HSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- HSAI
- Stock Information
- Founded
- AKRO 2017
- HSAI 2014
- Country
- AKRO United States
- HSAI China
- Employees
- AKRO N/A
- HSAI N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- HSAI
- Sector
- AKRO Health Care
- HSAI
- Exchange
- AKRO Nasdaq
- HSAI Nasdaq
- Market Cap
- AKRO 3.7B
- HSAI 2.8B
- IPO Year
- AKRO 2019
- HSAI 2023
- Fundamental
- Price
- AKRO $54.07
- HSAI $23.35
- Analyst Decision
- AKRO Buy
- HSAI Strong Buy
- Analyst Count
- AKRO 10
- HSAI 4
- Target Price
- AKRO $73.56
- HSAI $31.58
- AVG Volume (30 Days)
- AKRO 4.1M
- HSAI 2.6M
- Earning Date
- AKRO 11-07-2025
- HSAI 11-11-2025
- Dividend Yield
- AKRO N/A
- HSAI N/A
- EPS Growth
- AKRO N/A
- HSAI N/A
- EPS
- AKRO N/A
- HSAI 0.11
- Revenue
- AKRO N/A
- HSAI $347,701,639.00
- Revenue This Year
- AKRO N/A
- HSAI $61.81
- Revenue Next Year
- AKRO N/A
- HSAI $45.58
- P/E Ratio
- AKRO N/A
- HSAI $220.98
- Revenue Growth
- AKRO N/A
- HSAI 36.51
- 52 Week Low
- AKRO $21.34
- HSAI $4.02
- 52 Week High
- AKRO $58.40
- HSAI $30.85
- Technical
- Relative Strength Index (RSI)
- AKRO 68.61
- HSAI 43.88
- Support Level
- AKRO $53.40
- HSAI $22.91
- Resistance Level
- AKRO $54.31
- HSAI $23.97
- Average True Range (ATR)
- AKRO 0.26
- HSAI 1.00
- MACD
- AKRO -0.14
- HSAI 0.12
- Stochastic Oscillator
- AKRO 73.48
- HSAI 56.48
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About HSAI Hesai Group each ADS represents one Class B ordinary share
Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with enhanced advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.